Norway caps exenatide prescribing to 3 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2026
Page 3 of 5 of this archive, newest first.
Sending the same vial twice, under two names
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Ireland declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Continued treatment against continued placebo: the comparison that settled it
The regain trajectories, arm by arm, with the estimands named.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Custody, condition and the temperature nobody logged
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
The United Kingdom declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina caps exenatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The dose that got you here and the dose that keeps you here
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
A design note on withdrawal trials, and why the run-in matters
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
REWIND was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The United Kingdom declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
An interlaboratory comparison nobody had run
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Denmark caps liraglutide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Canada declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Mexico caps dulaglutide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Randomised withdrawal is the cleanest design in this field and the least discussed
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The submitted sample: the weakest link in the whole system
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.